Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

Inclusion Criteria: Glenohumeral OA: * Male or female, 35 to 80 years of age, inclusive, on the day of consent. * Painful symptoms associated with OA of the index glenohumeral joint for ≤3 months prior to the Screening Visit. * Grade 2 or 3 OA in the index glenohumeral joint based on the Samilson-Prieto classification system as confirmed by X-ray (axillary view and true anterior-posterior view) taken at the Screening Visit. Shoulder AC: * Male or female, 35 to 80 years of age, inclusive, on the day of consent. * Pain associated with AC of the index joint for ≥1 month but ≤ 6 months prior to the Screening Visit. * Limitations on both active and passive ROM ≥25% in at least 2 directions (e.g., forward flexion, abduction, and internal and external rotation assessed in a standardized protocol) compared with the contralateral shoulder or with normal values. * No X-ray evidence of OA of the index shoulder (axillary view and true anterior-posterior view) at the Screening Visit. * Agrees to complete a standardized, protocol-specified shoulder Home Exercise Program (HEP) starting 3 days after injection until the End of Study (EOS) Visit. Both: * Written consent to participate in the study * Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions * (BMI) ≤ 40 kg/m2 * Average daily mean shoulder pain with movement score ≥5.0 and ≤9.0 in the index shoulder (0 to 10 NRS) using the average daily ratings for at least …